Literature DB >> 28892919

Plasma Exchange as a Therapeutic Modality in a Rare Case of Cryptogenic New Onset Refractory Status Epilepticus (NORSE).

Manisha Shrivastava1, Smita Chouhan2, Seema Navaid3.   

Abstract

Refractory Status Epilepticus (RSE) not responding to any therapy and not associated with any aetiology has been termed as New Onset Refractory Status Epilepticus (NORSE). Guidelines for optimal management of cryptogenic NORSE are not clearly defined so far in the literature. Other than common medication, use of high-dose steroids, IV immune globulins and plasma exchanges in NORSE of unknown aetiology have been scarcely described. Immunomodulatory therapy like plasmapheresis is based on the fact that a pathological substance exists in the plasma that contributes to the disease process and its symptoms, which gets removed. We report a case of young female patient diagnosed as NORSE who responded to treatment with plasma exchange after becoming refractory to antiepileptic therapy and treatment with anaesthetic agents for recurrent seizers.

Entities:  

Keywords:  EEG; Epilepsy; Glassgow coma scale; Immunotherapy; Plasmapheresis

Year:  2017        PMID: 28892919      PMCID: PMC5583871          DOI: 10.7860/JCDR/2017/29878.10292

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  10 in total

Review 1.  Treatment of refractory status epilepticus: literature review and a proposed protocol.

Authors:  Nicholas S Abend; Dennis J Dlugos
Journal:  Pediatr Neurol       Date:  2008-06       Impact factor: 3.372

Review 2.  The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol.

Authors:  Simon Shorvon; Monica Ferlisi
Journal:  Brain       Date:  2011-09-13       Impact factor: 13.501

3.  New-onset refractory status epilepticus (NORSE)--The potential role for immunotherapy.

Authors:  Ayaz M Khawaja; Jennifer L DeWolfe; David W Miller; Jerzy P Szaflarski
Journal:  Epilepsy Behav       Date:  2015-05-23       Impact factor: 2.937

4.  Assessment of coma and impaired consciousness. A practical scale.

Authors:  G Teasdale; B Jennett
Journal:  Lancet       Date:  1974-07-13       Impact factor: 79.321

Review 5.  Plasmapheresis for refractory status epilepticus, part I: A scoping systematic review of the adult literature.

Authors:  F A Zeiler; M Matuszczak; J Teitelbaum; C J Kazina; L M Gillman
Journal:  Seizure       Date:  2016-10-19       Impact factor: 3.184

Review 6.  Plasmapheresis for refractory status epilepticus Part II: A scoping systematic review of the pediatric literature.

Authors:  F A Zeiler; M Matuszczak; J Teitelbaum; C J Kazina; L M Gillman
Journal:  Seizure       Date:  2016-11-19       Impact factor: 3.184

7.  The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity.

Authors:  E P V Wilder-Smith; E C H Lim; H L Teoh; V K Sharma; J J H Tan; B P L Chan; B K C Ong
Journal:  Ann Acad Med Singap       Date:  2005-08       Impact factor: 2.473

8.  Plasma exchange in cryptogenic new onset refractory status epilepticus.

Authors:  Judy Li; Christina Saldivar; Rama K Maganti
Journal:  Seizure       Date:  2012-10-12       Impact factor: 3.184

9.  Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy.

Authors:  Claire R E Gall; Odai Jumma; Rajiv Mohanraj
Journal:  Seizure       Date:  2013-01-18       Impact factor: 3.184

10.  De novo cryptogenic refractory multifocal febrile status epilepticus in the young adult: a review of six cases.

Authors:  I Van Lierde; W Van Paesschen; P Dupont; A Maes; R Sciot
Journal:  Acta Neurol Belg       Date:  2003-06       Impact factor: 2.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.